ArticleBMC nephrology2013
Poor histological lesions in IgA nephropathy may be reflected in blood and urine peptide profiling.
Article in BMC nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Dysregulated Protease Homeostasis Defines Primary FSGS.Kidney360 · 2026Article
- Proteomic Analysis of Circulating IgA1-Containing Immune Complexes in Patients with IgA Nephropathy.Kidney international reports · 2025Article
- Urinary peptidomics reveals proteases involved in idiopathic membranous nephropathy.BMC genomics · 2021Article
- Differential expression of peptides serves as an indicator of IgA nephropathy in pediatric patients.Experimental and therapeutic medicine · 2020Article
- Chronic kidney disease: a review of proteomic and metabolomic approaches to membranous glomerulonephritis, focal segmental glomerulosclerosis, and IgA nephropathy biomarkers.Proteome science · 2019Review
- Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?Disease markers · 2018Review
- Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy.Scientific reports · 2017Article
- Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis.Scientific reports · 2017Article
- Advances in urinary protein biomarkers for urogenital and non-urogenital pathologies.Biochemia medica · 2015Review
- Extracapillary proliferation in IgA nephropathy; recent findings and new ideas.Journal of nephropathology · 2015Review
- Biomarkers in IgA nephropathy: relationship to pathogenetic hits.Expert opinion on medical diagnostics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, leading to renal failure in 15% to 40% of cases. IgAN is diagnosed by renal biopsy, an invasive method that is not risk-free. We used blood and urine peptide profiles as a noninvasive method of linking IgAN-associated changes with histological lesions by Oxford classification.
methodsWe prospectively studied 19 patients with biopsy-proven IgAN and 14 healthy subjects from 2006 to 2009, excluding subjects with crescentic glomerulonephritis and collecting clinical and biochemical data at the time of diagnosis and during follow-up (24 months). Histological lesions were evaluated by Oxford classification. Proteomic analysis was performed by combining magnetic bead (MB) technology and mass spectrometry (MALDI-TOF MS) to obtain peptide profiles. Doubling of serum creatinine was considered a variable of poor renal prognosis.
resultsWe identified 55 peptides-13 in serum, 26 in plasma, and 16 in urine-that differentiated IgAN patients from healthy subjects. A significant association was noted between serum/plasma and urine peptides and histological findings-ie, tubulointerstitial damage, segmental glomerulosclerosis, and endocapillary injury.
conclusionsIn patients with IgAN, the use of noninvasive approaches, such as blood and urine proteomics, can provide valuable information beyond that of standard diagnostic techniques, allowing us to identify blood and urine peptide profiles that are associated with poor histological lesions in IgAN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.